Company | Name | Exchange | Sector | Industry | Market Cap | P/E Ratio | PEG Ratio | Last Trade Price | Day Change (%) | Fair Value | Fair Value Upside | Fair Value Label | Analyst Price Target | Analyst Target Upside | Overall Health |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Lonza Group | London | Healthcare | Biotechnology & Medical Research | £36.35B | 67.1x | GBX 50,335.11 | -1.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |||
arGEN X BV | London | Healthcare | Biotechnology & Medical Research | £29.99B | -928x | -11.63 | GBX 49,417.07 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Genmab | London | Healthcare | Biotechnology & Medical Research | £11.44B | 13.3x | 0.15 | GBX 17,989.73 | 0.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Qiagen NV | London | Healthcare | Biotechnology & Medical Research | £6.66B | 102.2x | -1.35 | GBX 3,082.78 | -14.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Zealand Pharma | London | Healthcare | Biotechnology & Medical Research | £5.46B | -42.9x | 1.53 | GBX 7,744.73 | 0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
BB Biotech L | London | Healthcare | Biotechnology & Medical Research | £1.79B | 16.1x | 0.2 | GBX 3,259.36 | 0.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Genus | London | Healthcare | Biotechnology & Medical Research | £1.14B | 144.3x | -1.93 | GBX 1,738 | -5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 31.7% Upside | Upgrade to Pro+ | |
Intellia Therapeutics | London | Healthcare | Biotechnology & Medical Research | £867.84M | -1.9x | 1.39 | GBX 847.33 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Geron Corp | London | Healthcare | Biotechnology & Medical Research | £767.85M | -5.1x | -1.43 | GBX 128.80 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
PureTech Health | London | Healthcare | Biotechnology & Medical Research | £342.37M | -6x | 0.07 | GBX 143 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Oxford BioMedica | London | Healthcare | Biotechnology & Medical Research | £342.30M | -2.3x | 0.02 | GBX 323 | -0.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Allergy Therapeutics | London | Healthcare | Biotechnology & Medical Research | £336.51M | -6.3x | -0.1 | GBX 7.06 | 8.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Verastem | London | Healthcare | Biotechnology & Medical Research | £197.46M | -1.7x | -0.13 | GBX 426.82 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Faron Pharmaceuticals Oy | London | Healthcare | Biotechnology & Medical Research | £183.09M | -4.6x | -1.16 | GBX 170 | 1.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Bioventix | London | Healthcare | Biotechnology & Medical Research | £152.94M | 19.1x | -5.65 | GBX 2,930 | -0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Avacta Group | London | Healthcare | Biotechnology & Medical Research | £150.80M | -4.7x | -0.13 | GBX 40.45 | -0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
4BASEBIO UK SOCIETAS | London | Healthcare | Biotechnology & Medical Research | £145.98M | -15.9x | 0.27 | GBX 1,117 | -2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Editas Medicine | London | Healthcare | Biotechnology & Medical Research | £119.83M | -0.7x | -0.18 | GBX 145.96 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Hvivo | London | Healthcare | Biotechnology & Medical Research | £107.84M | 6.1x | 0.01 | GBX 15.85 | -0.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Scancell | London | Healthcare | Biotechnology & Medical Research | £87.32M | -5x | 0.2 | GBX 8.50 | 0.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Transgene | London | Healthcare | Biotechnology & Medical Research | £76.06M | -3.1x | -0.12 | GBX 59.43 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Batm Advanced Comm | London | Healthcare | Biotechnology & Medical Research | £73.86M | -227.5x | 1.49 | GBX 16.92 | -0.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Corbus Pharmaceuticals Holdings | London | Healthcare | Biotechnology & Medical Research | £71.92M | -1.7x | -0.04 | GBX 583.82 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Biotec Pharmacon | London | Healthcare | Biotechnology & Medical Research | £68.62M | 125.9x | -2.11 | GBX 135.21 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Adverum Biotechnologies | London | Healthcare | Biotechnology & Medical Research | £68.60M | -0.7x | -0.02 | GBX 298.22 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Inovio Pharmaceuticals | London | Healthcare | Biotechnology & Medical Research | £56.39M | -0.4x | -0.02 | GBX 160.95 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Nordic Nanovector | London | Healthcare | Biotechnology & Medical Research | £53.14M | -42.9x | GBX 16.90 | -4.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |||
SkinBioTherapeutics | London | Healthcare | Biotechnology & Medical Research | £45.50M | -13.3x | -1.56 | GBX 19.92 | -0.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
OncoCyte | London | Healthcare | Biotechnology & Medical Research | £42.82M | -0.6x | -0.03 | GBX 201.61 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Futura | London | Healthcare | Biotechnology & Medical Research | £42.51M | -11.1x | -0.37 | GBX 13.99 | 8.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Novacyt SA | London | Healthcare | Biotechnology & Medical Research | £34.88M | -0.9x | 0.02 | GBX 50 | -1.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Relief Therapeutics Holding | London | Healthcare | Biotechnology & Medical Research | £34.69M | -0.4x | GBX 276.61 | 95% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |||
Shield Therapeutics | London | Healthcare | Biotechnology & Medical Research | £26.59M | -0.9x | -0.02 | GBX 3.40 | -1.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Sareum | London | Healthcare | Biotechnology & Medical Research | £22.47M | -4.3x | -0.61 | GBX 17.99 | -0.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Ananda Developments | Aquis Exchange | Healthcare | Biotechnology & Medical Research | £21.71M | -1.8x | 0.21 | GBX 0.50 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Celyad | London | Healthcare | Biotechnology & Medical Research | £20.60M | -2.6x | -0.04 | GBX 66.28 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Synairgen | London | Healthcare | Biotechnology & Medical Research | £20.18M | -0.5x | -0.1 | GBX 1.83 | -9.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Arecor Therapeutics | London | Healthcare | Biotechnology & Medical Research | £19.44M | -2.7x | -0.25 | GBX 50 | -2.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Palatin Technologies | London | Healthcare | Biotechnology & Medical Research | £18.97M | -0.6x | -0.02 | GBX 75.26 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Poolbeg Pharma | London | Healthcare | Biotechnology & Medical Research | £18.50M | -11.1x | -0.45 | GBX 3.76 | -0.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Optibiotix Health | London | Healthcare | Biotechnology & Medical Research | £17.52M | -5.7x | -0.07 | GBX 17.89 | -2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
ImmuPharma | London | Healthcare | Biotechnology & Medical Research | £16.37M | -6.6x | -0.21 | GBX 3.93 | -1.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Phaxiam Therapeutics | London | Healthcare | Biotechnology & Medical Research | £15.84M | -0.4x | GBX 159.60 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |||
MEI Pharma | London | Healthcare | Biotechnology & Medical Research | £13.78M | -0.4x | 0 | GBX 213.88 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Synlogic | London | Healthcare | Biotechnology & Medical Research | £12.74M | -0.5x | -0.01 | GBX 110.91 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Incanthera | Aquis Exchange | Healthcare | Biotechnology & Medical Research | £11.69M | -4.8x | -0 | GBX 10 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Hemogenyx Pharma | London | Healthcare | Biotechnology & Medical Research | £11.35M | -1.9x | -0.05 | GBX 315 | -0.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
IXICO | London | Healthcare | Biotechnology & Medical Research | £9.37M | -2.6x | 0.07 | GBX 10.11 | 1.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Aeterna Zentaris | London | Healthcare | Biotechnology & Medical Research | £8.46M | -0.2x | 0.02 | GBX 237 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
OpGen | London | Healthcare | Biotechnology & Medical Research | £8.21M | -0.3x | -0.01 | GBX 97.08 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ |